

Should recommendations about starting inhaled corticosteroids for asthma be based on symptom frequency: a post-hoc effect

Lancet, The

389, 157-166

DOI: [10.1016/s0140-6736\(16\)31399-x](https://doi.org/10.1016/s0140-6736(16)31399-x)

Citation Report

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 1 | The SYGMA programme of phase 3 trials to evaluate the efficacy and safety of budesonide/formoterol given "as needed"™ in mild asthma: study protocols for two randomised controlled trials. <i>Trials</i> , 2017, 18, 12. | 0.7 | 30 |
| 2 | Update in Asthma 2016. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017, 196, 548-557. | 2.5 | 5 |
| 3 | Therapeutic approaches to asthma-chronic obstructive pulmonary disease overlap. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 449-455. | 1.3 | 5 |
| 4 | Description of the protocol for the PRACTICAL study: a randomised controlled trial of the efficacy and safety of ICS/LABA reliever therapy in asthma. <i>BMJ Open Respiratory Research</i> , 2017, 4, e000217. | 1.2 | 15 |
| 5 | How should treatment approaches differ depending on the severity of asthma?. <i>Expert Review of Respiratory Medicine</i> , 2017, 11, 1-11. | 1.0 | 0 |
| 6 | Risks associated with managing asthma without a preventer: urgent healthcare, poor asthma control and over-the-counter reliever use in a cross-sectional population survey. <i>BMJ Open</i> , 2017, 7, e016688. | 0.8 | 52 |
| 7 | The impact of inappropriate use of short acting beta agonists in asthma. <i>Respiratory Medicine</i> , 2017, 131, 135-140. | 1.3 | 61 |
| 8 | New and Anticipated Therapies for Severe Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, S15-S24. | 2.0 | 23 |
| 11 | Improving the Efficiency of Respiratory Drug Delivery: A Review of Current Treatment Trends and Future Strategies for Asthma and Chronic Obstructive Pulmonary Disease. <i>Pulmonary Therapy</i> , 2017, 3, 267-281. | 1.1 | 19 |
| 12 | Decreased frequency of adenoidectomy by a 12-week nasal budesonide treatment. <i>Therapeutics and Clinical Risk Management</i> , 2017, Volume 13, 1309-1316. | 0.9 | 6 |
| 13 | The pediatric asthma yardstick. <i>Annals of Allergy, Asthma and Immunology</i> , 2018, 120, 559-579.e11. | 0.5 | 33 |
| 14 | Symbicort® Maintenance and Reliever Therapy (SMART) and the evolution of asthma management within the GINA guidelines. <i>Expert Review of Respiratory Medicine</i> , 2018, 12, 191-202. | 1.0 | 12 |
| 15 | Emerging Concepts in Evidence-Based Asthma Management. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2018, 39, 082-90. | 0.8 | 1 |
| 16 | Asthma exacerbation prediction: recent insights. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2018, 18, 117-123. | 1.1 | 35 |
| 17 | Controlling the Risk Domain in Pediatric Asthma through Personalized Care. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2018, 39, 036-044. | 0.8 | 4 |
| 18 | Asthma. <i>Lancet, The</i> , 2018, 391, 783-800. | 6.3 | 1,105 |
| 20 | Two pathways, one patient; UK asthma guidelines. <i>Thorax</i> , 2018, 73, 797-798. | 2.7 | 6 |
| 21 | Many patients labelled as having mild asthma do not have well-controlled asthma. <i>Respirology</i> , 2018, 23, 348-349. | 1.3 | 3 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 22 | After asthma: redefining airways diseases. <i>Lancet, The</i> , 2018, 391, 350-400. | 6.3 | 744 |
| 23 | Nationwide use of inhaled corticosteroids by South Korean asthma patients: an examination of the Health Insurance Review and Service database. <i>Journal of Thoracic Disease</i> , 2018, 10, 5405-5413. | 0.6 | 16 |
| 24 | Inhaled Corticosteroid Therapy for Asthma. , 2018, , 1-35. | | 0 |
| 25 | The further paradoxes of asthma management: time for a new approach across the spectrum of asthma severity. <i>European Respiratory Journal</i> , 2018, 52, 1800694. | 3.1 | 26 |
| 26 | Long-Term Trajectories of Mild Asthma in Adulthood and Risk Factors of Progression. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 2024-2032.e5. | 2.0 | 27 |
| 28 | Difficult vs. Severe Asthma: Definition and Limits of Asthma Control in the Pediatric Population. <i>Frontiers in Pediatrics</i> , 2018, 6, 170. | 0.9 | 59 |
| 29 | Anti-inflammatory Effects of <i>Distylium racemosum</i> Extract in a Mouse Model of Allergic Asthma. <i>Planta Medica International Open</i> , 2018, 5, e48-e54. | 0.3 | 0 |
| 30 | It is time to change the way we manage mild asthma: an update in GINA 2019. <i>Respiratory Research</i> , 2019, 20, 183. | 1.4 | 39 |
| 31 | GINA 2019: a fundamental change in asthma management. <i>European Respiratory Journal</i> , 2019, 53, 1901046. | 3.1 | 277 |
| 32 | The Global Initiative for Asthma (GINA): 25â€...years later. <i>European Respiratory Journal</i> , 2019, 54, 1900598. | 3.1 | 174 |
| 33 | House-Dust Mite Immunotherapy in Asthma: Uncertainties and Therapeutic Strategies. <i>Current Treatment Options in Allergy</i> , 2019, 6, 363-376. | 0.9 | 1 |
| 34 | Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial. <i>Lancet, The</i> , 2019, 394, 919-928. | 6.3 | 180 |
| 35 | Inhaled Corticosteroid Therapy for Asthma. , 2019, , 873-907. | | 0 |
| 36 | Controlled Trial of Budesonideâ€“Formoterol as Needed for Mild Asthma. <i>New England Journal of Medicine</i> , 2019, 380, 2020-2030. | 13.9 | 308 |
| 37 | A review of the burden and management of mild asthma in adults â€” Implications for clinical practice. <i>Respiratory Medicine</i> , 2019, 152, 97-104. | 1.3 | 13 |
| 38 | Asthma progression and mortality: the role of inhaled corticosteroids. <i>European Respiratory Journal</i> , 2019, 54, 1900491. | 3.1 | 96 |
| 39 | The multifaceted roles of FOXM1 in pulmonary disease. <i>Cell Communication and Signaling</i> , 2019, 17, 35. | 2.7 | 34 |
| 40 | Two Sides of the Same Coin?â€”Treatment of Chronic Asthma in Children and Adults. <i>Frontiers in Pediatrics</i> , 2019, 7, 62. | 0.9 | 11 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 41 | Extent, trends, and determinants of controller/reliever balance in mild asthma: a 14-year population-based study. <i>Respiratory Research</i> , 2019, 20, 44. | 1.4 | 1 |
| 42 | Is it time to move away from short-acting beta-agonists in asthma management?. <i>European Respiratory Journal</i> , 2019, 53, 1802223. | 3.1 | 23 |
| 44 | The most fundamental change in asthma management in 30 years?. <i>European Respiratory Journal</i> , 2019, 54, 1901583. | 3.1 | 3 |
| 45 | Airway function throughout the lifespan: Pediatric origins of adult respiratory disease. <i>Pediatric Investigation</i> , 2019, 3, 236-244. | 0.6 | 9 |
| 46 | Response: The most fundamental change in asthma management in 30 years?. <i>European Respiratory Journal</i> , 2019, 54, 1901860. | 3.1 | 2 |
| 47 | Efficacy of Shegan Mahuang Decoction for asthma. <i>Medicine (United States)</i> , 2019, 98, e17845. | 0.4 | 5 |
| 48 | Does a Patient-Directed Financial Incentive Affect Patient Choices About Controller Medicines for Asthma? A Discrete Choice Experiment and Financial Impact Analysis. <i>Pharmacoeconomics</i> , 2019, 37, 227-238. | 1.7 | 4 |
| 49 | Oral corticosteroid-dependent asthma. <i>Current Opinion in Pulmonary Medicine</i> , 2019, 25, 51-58. | 1.2 | 26 |
| 50 | Small Airway Dysfunction by Impulse Oscillometry in Symptomatic Patients with Preserved Pulmonary Function. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 229-235.e3. | 2.0 | 47 |
| 51 | The history and future of short-acting beta ₂ -agonist therapy in asthma. <i>Respirology</i> , 2020, 25, 246-248. | 1.3 | 6 |
| 52 | As-needed anti-inflammatory reliever therapy for asthma management: evidence and practical considerations. <i>Clinical and Experimental Allergy</i> , 2021, 51, 873-882. | 1.4 | 6 |
| 53 | Asthma-Related Health Outcomes Associated with Short-Acting Î2-Agonist Inhaler Use: An Observational UK Study as Part of the SABINA Global Program. <i>Advances in Therapy</i> , 2020, 37, 4190-4208. | 1.3 | 66 |
| 54 | The burden of exacerbations in mild asthma: a systematic review. <i>ERJ Open Research</i> , 2020, 6, 00359-2019. | 1.1 | 33 |
| 55 | Treatment strategies for asthma: reshaping the concept of asthma management. <i>Allergy, Asthma and Clinical Immunology</i> , 2020, 16, 75. | 0.9 | 55 |
| 56 | Advances with glucocorticoids in the treatment of asthma: state of the art. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 2305-2316. | 0.9 | 23 |
| 57 | Long-term effects of asthma medication on asthma symptoms: an application of the targeted maximum likelihood estimation. <i>BMC Medical Research Methodology</i> , 2020, 20, 307. | 1.4 | 1 |
| 58 | A golden age of asthma research. <i>European Respiratory Journal</i> , 2020, 56, 2003820. | 3.1 | 2 |
| 59 | Asthma maintenance and reliever therapy. <i>Annals of Allergy, Asthma and Immunology</i> , 2020, 125, 150-155. | 0.5 | 11 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 60 | Cu-Ben-Fang-Xiao Decoction Ameliorated Murine Asthma in Remission Stage by Modulating Microbiota-Acetate-Tregs Axis. <i>Frontiers in Pharmacology</i> , 2020, 11, 549. | 1.6 | 21 |
| 61 | The comparison of fluticasone propionate/formoterol with fluticasone propionate/salmeterol for paediatric asthma: a meta-analysis of randomized controlled trials. <i>Postepy Dermatologii I Alergologii</i> , 2021, 38, 377-383. | 0.4 | 0 |
| 62 | Heterogeneity of Mild to Moderate Persistent Asthma in Children: Confirmation by Latent Class Analysis and Association with 1-Year Outcomes. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2617-2627.e4. | 2.0 | 21 |
| 63 | The efficacy of mometasone furoate for children with asthma: a meta-analysis of randomized controlled trials. <i>Postepy Dermatologii I Alergologii</i> , 2021, 38, 740-745. | 0.4 | 0 |
| 64 | Immune Modulation in Asthma: Current Concepts and Future Strategies. <i>Respiration</i> , 2020, 99, 566-576. | 1.2 | 16 |
| 65 | New approach to intermittent and mild asthma therapy: evolution or revolution in the GINA guidelines?. <i>Clinical and Translational Allergy</i> , 2020, 10, 19. | 1.4 | 13 |
| 66 | Predictive value of blood eosinophils and exhaled nitric oxide in adults with mild asthma: a prespecified subgroup analysis of an open-label, parallel-group, randomised controlled trial. <i>Lancet Respiratory Medicine</i> , 2020, 8, 671-680. | 5.2 | 81 |
| 67 | Effective Asthma Management: Is It Time to Let the AIR out of SABA?. <i>Journal of Clinical Medicine</i> , 2020, 9, 921. | 1.0 | 25 |
| 68 | Patient preferences for symptom-driven or regular preventer treatment in mild to moderate asthma: findings from the PRACTICAL study, a randomised clinical trial. <i>European Respiratory Journal</i> , 2020, 55, 1902073. | 3.1 | 33 |
| 69 | New Therapeutic Strategies for Asthma. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 517. | 3.8 | 5 |
| 70 | Outpatient Management of Chronic Asthma in 2020. <i>JAMA - Journal of the American Medical Association</i> , 2020, 323, 561. | 3.8 | 12 |
| 71 | Reducing the hidden burden of severe asthma: recognition and referrals from primary practice. <i>Journal of Asthma</i> , 2021, 58, 849-854. | 0.9 | 8 |
| 73 | Budesonide-formoterol reliever therapy in intermittent versus mild persistent asthma. <i>European Respiratory Journal</i> , 2021, 57, 2003064. | 3.1 | 10 |
| 74 | The management of mild asthma. <i>European Respiratory Journal</i> , 2021, 57, 2003051. | 3.1 | 15 |
| 76 | 2021 Canadian Thoracic Society Guideline – A focused update on the management of very mild and mild asthma. <i>Canadian Journal of Respiratory, Critical Care, and Sleep Medicine</i> , 2021, 5, 205-245. | 0.2 | 22 |
| 77 | Reply: About the recommendation of the GINA strategy report on asthma step 1. <i>European Respiratory Journal</i> , 2021, 57, 2004226. | 3.1 | 2 |
| 79 | Uncontrolled asthma across GINA treatment steps 2-5 in a large US patient cohort. <i>Journal of Asthma</i> , 2022, 59, 1051-1062. | 0.9 | 13 |
| 80 | Hospital admission rate in children and adolescents with mild persistent asthma. <i>Pediatric Pulmonology</i> , 2021, 56, 1889-1895. | 1.0 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 81 | New insights from GINA 2019/2020â€”Focus on early anti-inflammatory therapy. Wiener Klinische Wochenschrift, 2021, 133, 1215-1220. | 1.0 | 1 |
| 82 | Incidence and predictors of asthma exacerbations in middle-aged and older adults: the Rotterdam Study. ERJ Open Research, 2021, 7, 00126-2021. | 1.1 | 1 |
| 83 | The prevalence and outcome of short-acting Î²2-agonists overuse in asthma patients in Taiwan. Npj Primary Care Respiratory Medicine, 2021, 31, 19. | 1.1 | 10 |
| 84 | Positioning As-needed Budesonideâ€”Formoterol for Mild Asthma: Effect of Prestudy Treatment in Pooled Analysis of SYGMA 1 and 2. Annals of the American Thoracic Society, 2021, 18, 2007-2017. | 1.5 | 17 |
| 85 | Once-Daily vs. Twice-Daily Administration of Inhaled Budesonide for Mild and Moderate Well-Controlled Childhood Asthma: A Randomized, Controlled Trial. Indian Journal of Pediatrics, 2022, 89, 13-18. | 0.3 | 2 |
| 87 | Evaluation of efficiency and safety of oral corticosteroid therapy in children patients with exacerbations of asthma. Medicine (United States), 2021, 100, e26250. | 0.4 | 1 |
| 88 | Combination fixed-dose Î²2 agonist and steroid inhaler as required for adults or children with mild asthma: a Cochrane systematic review. BMJ Evidence-Based Medicine, 2022, 27, 178-184. | 1.7 | 13 |
| 89 | Sex differences in excessive oral corticosteroid exposure in poor adherent adult asthmatics overusing short-acting Î²2-agonists. Minerva Medica, 2021, , . | 0.3 | 0 |
| 91 | The controversial role of as-needed short-acting Î²2-agonist monotherapy in mild asthma: Short review of current guidelines. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2021, 5, 273-275. | 0.2 | 0 |
| 92 | Non-adherence and sub-optimal treatment with asthma medications in young adults: a population-based cohort study. Journal of Asthma, 2021, , 1-9. | 0.9 | 5 |
| 94 | Oral corticosteroids stewardship for asthma in adults and adolescents: A position paper from the Thoracic Society of Australia and New Zealand. Respiriology, 2021, 26, 1112-1130. | 1.3 | 35 |
| 95 | Revisiting Mild Asthma. Chest, 2022, 161, 26-39. | 0.4 | 6 |
| 96 | Mild/Moderate Asthma Network in Italy (MANI): a long-term observational study. Journal of Asthma, 2022, 59, 1908-1913. | 0.9 | 4 |
| 97 | Moving towards a Treatable Traits model of care for the management of obstructive airways diseases. Respiratory Medicine, 2021, 187, 106572. | 1.3 | 29 |
| 98 | The Saudi Initiative for Asthma - 2021 Update: Guidelines for the diagnosis and management of asthma in adults and children. Annals of Thoracic Medicine, 2021, 16, 4. | 0.7 | 34 |
| 100 | Budesonide/formoterol TurbuhalerÂ® as needed in mild asthma: results of SYGMA-1 and SYGMA-2 trials (SYmbicortÂ® Given as needed in Mild Asthma). Pulmonologiya, 2019, 29, 419-427. | 0.2 | 1 |
| 101 | The cost of asthma medicines. Australian Prescriber, 2018, 41, 34-36. | 0.5 | 11 |
| 102 | Managing adult asthma: The 2019 GINA guidelines. Cleveland Clinic Journal of Medicine, 2020, 87, 569-575. | 0.6 | 43 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 103 | The Saudi Initiative for Asthma - 2019 Update: Guidelines for the diagnosis and management of asthma in adults and children. <i>Annals of Thoracic Medicine</i> , 2019, 14, 3. | 0.7 | 45 |
| 104 | The global initiative for asthma guidelines (2019): change in the recommendation for the management of mild asthma based on the SYGMA-2 trial – A critical appraisal. <i>Lung India</i> , 2020, 37, 169. | 0.3 | 17 |
| 105 | Efficacy of Allergen Immunotherapy for Allergic Asthma in Real World Practice. <i>Allergy, Asthma and Immunology Research</i> , 2020, 12, 99. | 1.1 | 15 |
| 106 | The predictive role of small airway dysfunction and airway inflammation biomarkers for asthma in preschool and school-age children: a study protocol for a prospective cohort study. <i>Translational Pediatrics</i> , 2021, 10, 2630-2638. | 0.5 | 1 |
| 107 | Global Initiative for Asthma Strategy 2021. <i>Respirology</i> , 2022, 27, 14-35. | 1.3 | 31 |
| 108 | Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes. <i>European Respiratory Journal</i> , 2022, 59, 2102730. | 3.1 | 218 |
| 109 | Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 17-35. | 2.5 | 196 |
| 111 | Mild bronchial asthma: a modern treatment concept. <i>Meditinskiy Sovet</i> , 2019, , 29-36. | 0.1 | 0 |
| 112 | Today’s improvement in asthma treatment: role of MART and Easyhaler. <i>Multidisciplinary Respiratory Medicine</i> , 2020, 15, 649. | 0.6 | 3 |
| 113 | Global Initiative for Asthma Strategy 2021. Executive Summary and Rationale for Key Changes. <i>Archivos De Bronconeumologia</i> , 2022, 58, 35-51. | 0.4 | 31 |
| 114 | Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, S1-S18. | 2.0 | 66 |
| 115 | Bronchial asthma – a new paradigm in GINA clinical recommendations. <i>Đart 1. Tuberculosis Lung Diseases HIV Infection</i> , 2020, . | 0.3 | 0 |
| 116 | Management and treatment of bronchial asthma in adults and children on the basis of new guidelines. <i>Postepy Higieny I Medycyny Doswiadczalnej</i> , 2020, 74, 283-300. | 0.1 | 0 |
| 117 | Bronchial asthma – a new paradigm in GINA clinical recommendations. <i>Đart 2. Tuberculosis Lung Diseases HIV Infection</i> , 2020, . | 0.3 | 0 |
| 118 | Guidelines for the management of asthma in adults and adolescents: Position statement of the South African Thoracic Society – 2021 update. <i>African Journal of Thoracic and Critical Care Medicine</i> , 2021, 24, . | 0.3 | 5 |
| 119 | Perspectives of mild asthma patients on maintenance versus as-needed preventer treatment regimens: a qualitative study. <i>BMJ Open</i> , 2022, 12, e048537. | 0.8 | 10 |
| 120 | Effect of combined glucocorticoid therapy on bronchial asthma dynamics. <i>Allergologia Et Immunopathologia</i> , 2022, 50, 68-74. | 1.0 | 1 |
| 121 | An independent in-depth analysis proposing adjusted Global Initiative on Asthma Step 1 – 2 treatment suggestions. <i>Clinical and Experimental Allergy</i> , 2022, 52, 493-511. | 1.4 | 3 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 122 | FeNO in Asthma. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2022, 43, 635-645. | 0.8 | 23 |
| 123 | Risk of pneumonia in asthmatic children using inhaled corticosteroids: a nested case-control study in a birth cohort. <i>BMJ Open</i> , 2022, 12, e051926. | 0.8 | 1 |
| 124 | New approaches to basic treatment of asthma. <i>Modern Medical Technologies</i> , 2021, , 19-25. | 0.1 | 0 |
| 127 | Immune Repertoire and Advancements in Nanotherapeutics for the Impediment of Severe Steroid Resistant Asthma (SSR). <i>International Journal of Nanomedicine</i> , 2022, Volume 17, 2121-2138. | 3.3 | 0 |
| 129 | Prospective study of factors associated with asthma attack recurrence (ATTACK) in children from three Ecuadorian cities during COVID-19: a study protocol. <i>BMJ Open</i> , 2022, 12, e056295. | 0.8 | 0 |
| 130 | Understanding the journeys of patients with an asthma exacerbation requiring urgent therapy at a primary care clinic. <i>BMC Pulmonary Medicine</i> , 2022, 22, . | 0.8 | 5 |
| 131 | Understanding the Updates in the Asthma Guidelines. <i>Seminars in Respiratory and Critical Care Medicine</i> , 0, , . | 0.8 | 0 |
| 132 | Short-Acting Beta-2-Agonist Exposure and Severe Asthma Exacerbations: Analysis of the Recently Reported Findings From the European and North American SABINA Datasets. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 2310-2311. | 2.0 | 2 |
| 133 | The association between sociodemographic status and COPD and asthma mortality, DALY and YLD in southern China, 2005â€“2015. <i>Public Health</i> , 2022, 212, 102-110. | 1.4 | 0 |
| 134 | Airway inflammation and hyperresponsiveness in subjects with respiratory symptoms and normal spirometry. <i>European Respiratory Journal</i> , 2023, 61, 2201194. | 3.1 | 5 |
| 135 | Sounding the alarmâ€”The role of alarmin cytokines in asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2023, 78, 402-417. | 2.7 | 17 |
| 136 | A Call for the United States to Accelerate the Implementation of Reliever Combination Inhaled Corticosteroidâ€”Formoterol Inhalers in Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2023, 207, 390-405. | 2.5 | 9 |
| 137 | Is mild asthma truly mild? The patientsâ€™ real-life setting. <i>Expert Review of Respiratory Medicine</i> , 2022, 16, 1263-1272. | 1.0 | 1 |
| 138 | The Changing Asthma Management Landscape and Need for Appropriate SABA Prescription. <i>Advances in Therapy</i> , 2023, 40, 1301-1316. | 1.3 | 6 |
| 139 | Key recommendations for primary care from the 2022 Global Initiative for Asthma (GINA) update. <i>Npj Primary Care Respiratory Medicine</i> , 2023, 33, . | 1.1 | 73 |
| 146 | As Needed LABA/ICS in Asthma (START)-2019. , 2023, , 305-307. | | 0 |